No Data
"Smart money" is betting on china becoming a trend: In Q3, the prototype of the "big short" increased shareholding in Alibaba and other Chinese concepts, while the rising fund Keystone established positions in three major etfs.
In the third quarter, the fund under Michael Burry increased its shareholding in Alibaba by 0.045 million shares to nearly 0.2 million shares, doubled its hold positions in jd.com to 0.5 million shares, and increased its shareholding in baidu by 0.05 million shares to 0.125 million shares. At the end of the quarter, it held three Chinese concept stocks valued at 54 million dollars, accounting for 65% of the total fund's stock holdings. Meanwhile, the fund bought corresponding put options for these three Chinese concept stocks to hedge risks.
Baidu Fortifies AI Suite With Two New Tools
Express News | Ishares MSCI China ETF Down 2.3%, Ishares China Large Cap ETF Down 2.8%, Kraneshares CSI China Internet ETF Down 3.2%
Market Chatter: Baidu to Release AI-Powered Glasses in November
[Brokerage Focus] Soochow Securities maintains a "buy" rating on Baidu Group (09888), indicating that the business will still be affected by internal business AI transformation in the short term.
Jingu Financial News | Soochow Securities issued a research report, forecasting that Baidu Group (09888) will have a revenue of 33.4 billion yuan in Q3 2024, a 3% year-on-year decline; with Baidu's core revenue at 26.3 billion yuan, a 1% year-on-year decline. The company is expected to achieve an adjusted operating profit of 6.6 billion yuan, with Baidu's core adjusted operating profit at 6.3 billion yuan, and an adjusted operating profit margin of 24%. The company is forecasted to achieve an adjusted net income of 6.2 billion yuan. The firm predicts that in Q3 2024, Baidu's core revenue will be 26.3 billion yuan, down 1% year-on-year, with advertising revenue expected to drop nearly 5% due to macroeconomic factors, although clients in the education, e-commerce, and other industries are
China Fiscal Policy Announcement Seems Underwhelming
No Data
No Data
No Data
